Effects of recombinant human interleukin-11 on LPS-induced intestinal epithelial cell injury in rats

CAI Na; FENG Zhi-Chun; WANG Rui-Juan

doi:10.7499/j.issn.1008-8830.2014.05.017

PDF(1495 KB)

Chinese Journal of Contemporary Pediatrics ›› 2014, Vol. 16 ›› Issue (5) : 529-533. DOI: 10.7499/j.issn.1008-8830.2014.05.017

EXPERIMENTAL RESEARCH

Effects of recombinant human interleukin-11 on LPS-induced intestinal epithelial cell injury in rats

CAI Na, FENG Zhi-Chun, WANG Rui-Juan

Author information +

History +

Abstract

Objective To study the effects of recombinant human interleukin-11 (rhIL-11) on the proliferation and apoptosis of rat intestinal epithelial cell line (IEC-6). Methods IEC-6 cells were treated with LPS to establish necrotizing enterocolitis (NEC) model in vitro. rhIL-11 (100 ng/mL) was administered following LPS treatment and these cells were used as the IL-11 treatment group. The cells treated with normal saline only served as the control group. MTT assay was used to determine an optimal concentration (5-200 μg/mL) and time (1-24 h). MTT assay was used to measure the proliferation of IEC-6 cells at 3, 6, 9 and 12 hours after rhIL-11 treatment. Flow cytometry was used to evaluate the apoptosis of IEC-6 cells. Results IEC-6 cells treated with various concentrations of LPS at various time points showed a lower proliferation than the control group (P<0.05). After 9 hours of rhIL-11 treatment, the proliferation activity of IEC-6 cells in the IL-11 treatment group significantly increased compared with the NEC model group without rhIL-11 treatment (P<0.05), reaching to the level of the control group. The total apoptotic and necrotic rate of IEC-6 cells in the IL-11 treatment group decreased significantly compared with the NEC model group without rhIL-11 treatment (P<0.01), but were still higher than the control group (P<0.05). Conclusions rhIL-11 can promote proliferation and reduce apoptotic and necrotic rates of IEC-6 cells treated with LPS.

Key words

Necrotizing enterocolitis / Recombinant human interleukin-11 / Lipopolysaccharide / Intestinal epithelial cell-6

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

CAI Na, FENG Zhi-Chun, WANG Rui-Juan. Effects of recombinant human interleukin-11 on LPS-induced intestinal epithelial cell injury in rats[J]. Chinese Journal of Contemporary Pediatrics. 2014, 16(5): 529-533 https://doi.org/10.7499/j.issn.1008-8830.2014.05.017

References

[1] Yee WH, Soraisham AS, Shah VS, et al. Incidence and timing of presentation of necrotizing enterocolitis in preterm infants[J]. Pediatrics, 2012, 129(2): 298-304.
[2] Berman L, Moss RL. Necrotizing enterocolitis: an update[J]. Semin Fetal Neonatal Med, 2011, 16(3): 145-150.
[3] Kuenzler KA, Pearson PY, Schwartz MZ. IL-11 pretreatment reduces cell death after intestinal ischemia-reperfusion[J]. J Surg Res, 2002, 108(2): 268-272.
[4] Du X, Liu Q, Yang Z, et al. Protective effects of interleukin-11 in a murine model of ischemic bowel necrosis[J]. Am J Physiol, 1997, 272(3Pt 1): 545-552.
[5] Fiore NF, Ledniczky G, Liu Q, et al. Comparison of interleukin-11 and epidermal growth factor on residual small intestine after massive small bowel resection[J]. J Pediatr Surg, 1998, 33(1): 24-29.
[6] Dickinson EC, Tuncer R, Nadler EP, et al. Recombinant human interleukin-11 prevents mucosal atrophy and bowel shortening in the defunctionalized intestine[J]. J Pediatr Surg, 2000, 35(7): 1079-1083.
[7] Peterson RL, Wang L, Albert L, et al. Molecular effects of recombinant human interleukin-11 in the HLA-B27 rat model of inflammatory bowel disease[J]. Lab Invest, 1998, 78(12): 1503-1512.
[8] McElroy SJ, Hobbs S, Kallen M, et al. Transactivation of EGFR by LPS Induces COX-2 Expression in Enterocytes[J]. PLoS One, 2012, 7(5): 38373.
[9] Richter JM, Schanbacher BL, Huang H, et al. LPS-binding protein enables intestinal epithelial restitution despite LPS exposure[J]. J Pediatr Gastroenterol Nutr, 2012, 54(5): 639-644.
[10] 王瑞娟, 彭瑞云, 付凯飞, 等. rhIL-11 对中子辐射IEC-6 细胞IL-11RA和gp130 表达的影响[J]. 中华放射医学与防护杂志, 2006, 26(5): 438-441.
[11] Schwertschlag US, Trepicchio WL, Dykstra KH, et al. Hematopoietic, immunomodulatory and epithelial effects of interleukin-11[J]. Leukemia, 1999, 13(9): 1307-1315.
[12] Greenwood-Van Meerveld B, Tyler K, Keith JC Jr. Recombinant human interleukin-11 modulates ion transport and mucosal inflammation in the small intestine and colon[J]. Lab Invest, 2000, 80(8): 1269-1280.
[13] Nadler EP, Stanford A, Zhang XR, et al. Intestinal cytokine gene expression in infants with acute necrotizing enterocolitis: interleukin-11 mRNA expression inversely correlates with extent of disease[J]. J Pediatr Surg, 2001, 36(8): 1122-1129.
[14] Kuenzler KA, Pearson PY, Schwartz MZ. IL-11 pretreatment reduces cell death after intestinal ischemia-reperfusion[J]. J Surg Res, 2002, 108(2): 268-272.
[15] Du X, Liu Q, Yang Z, et al. Protective effects of interleukin-11 in a murine model of ischemic bowel necrosis[J]. Am J Physiol, 1997, 272(3 Pt 1): 545-552.
[16] Dickinson EC, Tuncer R, Nadler EP, et al. Recombinant human interleukin-11 prevents mucosal atrophy and bowel shortening in the defunctionalized intestine[J]. J Pediatr Surg, 2000, 35(7): 1079-1083.
[17] 王瑞娟, 彭瑞云, 高亚兵, 等. IL-11对中子辐射小鼠肠道IL-11受体表达的影响[J]. 中国体视学与图像分析, 2006, 11(4): 258-262.
[18] Mollen KP, Gribar SC, Anand RJ, et al. Increased expression and internalization of the endotoxin coreceptor CD14 in enterocytes occurs as an early event in the development of experimental necrotizing enterocolitis[J]. J Pediatr Surg, 2008, 43(6): 1175-1181.
[19] Peterson RL, Wang L, Albert L, et al. Molecular effects of recombinant human interleukin-11 in the HLA-B27 rat model of inflammatory bowel disease[J]. Lab Invest, 1998, 78(12): 1503-1512.